University of Illinois-led Study Reveals Antifungal Drug Improves Important Cystic Fibrosis Biomarker: Team forms cystetic Medicines

University of Illinois-led Study Reveals Antifungal Drug Improves Important Cystic Fibrosis Biomarker Team forms cystetic Medicines

Researchers from the University of Illinois Urbana-Champaign alongside the University of Iowa recently partnered in a study and discovered that a particular drug commonly used to treat fungal infections known as amphotericin B, actually contributed to improved biomarkers in lung tissue cultures and noses of patients afflicted with cystic fibrosis. As it turns out, those patients with a missing or defective ion channel that lines their lungs, CFTR, actually can make it far easier for patients to succumb to lung infection. A class of drugs known as modulators are used to help some, contingent on the specific genetic mutation behind their symptoms. In this research clinical study, participants were recruited out of a group of individuals, representing 10% of the total, who lack the ability to respond to modulator treatments. Does amphotericin B, an antifungal drug, benefit all patients regardless of any mutations?   Dr. Martin Burke, professor of chemistry at University of Illinois and the associate dean for research for the Carle Illinois College of Medicine, believes the answer is in the affirmative. They have now formed a startup known as cystetic Medicines, raising $25 million fr...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee